Coronavirus vaccines are moving towards clinical trials

Image
ANI US
Last Updated : Apr 09 2020 | 2:50 PM IST

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments.

In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory authorities.

In just a few months, more than two dozen companies have announced promising vaccine programmes, speeding through the early stages of testing unlike ever before, The Strait Times reported.

On Wednesday, Novavax, a Maryland-based biotech company, said its vaccine candidate had stimulated a powerful immune response in lab and animal experiments, producing antibodies that could fight off the coronavirus. The vaccine is set to begin human trials in Australia in mid-May.

While a final product that would be widely available is still a year or more away, the Novavax effort is one of many ready to be tested in people.

A vaccine made by biotech company Moderna is already in a clinical trial, which started March 15.

Another one, developed by Inovio Pharmaceuticals, was injected into the first adult volunteers on Monday.

Health care giant Johnson and Johnson expects to start clinical trials in September and has received a nearly US$500 million partnership via a division of the US Department of Health and Human Services.

In addition, experimental vaccines developed by researchers at the University of Pittsburgh and Baylor College of Medicine are also waiting for permission from the Food and Drug Administration to begin testing in people.

"We're all trying to do something which we have almost no precedents for, which is accelerating a vaccine in the middle of a pandemic," said Peter Hotez, co-director of the Texas Children's Hospital Centre for Vaccine Development at Baylor College of Medicine.

There is no proven treatment or vaccine yet against Covid-19, which has already affected more than one million people around the world so far.

A vaccine would be the best way to stop further spread of the coronavirus because it enhances the immune system's natural defences.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 09 2020 | 2:26 PM IST

Next Story